Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,034 across all filing types
Latest filing 2025-05-23 Board/Management Inform…
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Appointment
Board/Management Information Classification · 100% confidence The document is a formal announcement addressed to stock exchanges regarding the outcome of a Board Meeting held on May 23, 2025. It details the appointment of a new Additional Director and Executive Director (Global CFO) of the company, including the term of appointment and brief profile. The document references compliance with SEBI Listing Regulations and includes an annexure with detailed disclosure information about the appointment. There are no financial statements, earnings data, or detailed management discussion of financial results. The content focuses solely on management changes at the board level. Therefore, this document fits the category of Board/Management Information (MANG). The document length (7002 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive announcement of a board appointment.
2025-05-23 English
Outcome of Board Meeting
Regulatory Filings
2025-05-23 English
Options to purchase securities
Share Issue/Capital Change Classification · 95% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) regarding the grant of employee stock options under the company's Employee Stock Option Scheme, 2016. It references compliance with SEBI Listing Regulations and provides detailed disclosure as per Regulation 30 of SEBI Listing Regulations. The content focuses on the grant of stock options, including number of options, pricing, vesting period, and other terms. There is no financial performance data, earnings information, or management discussion. The document is an announcement of a capital-related event (grant of stock options) rather than a full financial report or earnings release. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or stock option grants.
2025-05-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a formal invitation and announcement of an upcoming earnings call scheduled for May 26, 2025, regarding Glenmark Pharmaceuticals' Q4 FY 2024-25 results. It provides dial-in details and contact information but does not contain any financial data or results itself. The document length is short (1975 characters) and serves as a notification rather than the actual earnings release or call transcript. According to the classification rules, such announcements of calls are best classified as Call Transcript (CT) only if they contain the transcript, but here it is only an invitation. Since it is an announcement of an earnings call, the best fit is Call Transcript (CT) category as it relates directly to the earnings call event, even though the transcript is not included yet. Confidence is high due to clear mention of earnings call details and no financial data present.
2025-05-19 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-05-12 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a notification addressed to stock exchanges about an upcoming Board Meeting scheduled for May 23, 2025. The purpose of the meeting is to consider and approve the audited financial results for the quarter and year ended March 31, 2025, and to consider dividend recommendations. It also mentions the closure of the trading window for insider trading compliance. The document does not contain the financial results themselves, nor detailed financial data or analysis. It is an announcement of a future event (Board Meeting) and the intention to approve financial results, not the results or report itself. The document length is short (2070 characters), and it serves as a formal notice to the exchange. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-05-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.